Factor inhibiting HIF-1 (FIH-1) modulates protein interactions of apoptosis-stimulating p53 binding protein 2 (ASPP2)

被引:47
|
作者
Janke, Kirsten [1 ]
Brockmeier, Ulf [1 ]
Kuhlmann, Katja [2 ]
Eisenacher, Martin [2 ]
Nolde, Jan [3 ]
Meyer, Helmut E. [2 ]
Mairbaeurl, Heimo [4 ]
Metzen, Eric [1 ]
机构
[1] Univ Duisburg Essen, Fac Med, Inst Physiol, D-45147 Essen, Germany
[2] Ruhr Univ Bochum, Med Proteom Ctr, D-44780 Bochum, Germany
[3] Med Univ Lubeck, Dept Surg, D-23538 Lubeck, Germany
[4] Univ Heidelberg Hosp, Dept Internal Med Sports Med, D-69120 Heidelberg, Germany
关键词
Cell polarity; Hydroxylation; Hypoxia; Protein interaction; ANKYRIN REPEAT DOMAIN; BLOOD-BRAIN-BARRIER; ASPARAGINYL HYDROXYLASE; BETA-HYDROXYLATION; HYPOXIA; ALPHA; NOTCH; PERMEABILITY; HIF-1-ALPHA; STABILITY;
D O I
10.1242/jcs.117564
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The asparaginyl hydroxylase factor inhibiting HIF-1 (FIH-1) is an important suppressor of hypoxia-inducible factor (HIF) activity. In addition to HIF-alpha, FIH-1 was previously shown to hydroxylate other substrates within a highly conserved protein interaction domain, termed the ankyrin repeat domain (ARD). However, to date, the biological role of FIH-1-dependent ARD hydroxylation could not be clarified for any ARD-containing substrate. The apoptosis-stimulating p53-binding protein (ASPP) family members were initially identified as highly conserved regulators of the tumour suppressor p53. In addition, ASPP2 was shown to be important for the regulation of cell polarity through interaction with partitioning defective 3 homolog (Par-3). Using mass spectrometry we identified ASPP2 as a new substrate of FIH-1 but inhibitory ASPP (iASPP) was not hydroxylated. We demonstrated that ASPP2 asparagine 986 (N986) is a single hydroxylation site located within the ARD. ASPP2 protein levels and stability were not affected by depletion or inhibition of FIH-1. However, FIH-1 depletion did lead to impaired binding of Par-3 to ASPP2 while the interaction between ASPP2 and p53, apoptosis and proliferation of the cancer cells were not affected. Depletion of FIH-1 and incubation with the hydroxylase inhibitor dimethyloxalylglycine (DMOG) resulted in relocation of ASPP2 from cell-cell contacts to the cytosol. Our data thus demonstrate that protein interactions of ARD-containing substrates can be modified by FIH-1-dependent hydroxylation. The large cellular pool of ARD-containing proteins suggests that FIH-1 can affect a broad range of cellular functions and signalling pathways under certain conditions, for example, in response to severe hypoxia.
引用
收藏
页码:2629 / 2640
页数:12
相关论文
共 50 条
  • [21] Oncogenic splicing of the Apoptosis-Stimulating Protein of p53-2 (ASPP2) is an initiating step in leukemogenesis facilitating acquisition of structural genomic mutations
    Kamna-Schittenhelm, K.
    Mau-Holzmann, U.
    Lopez, C.
    Schittenhelm, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 146 - 146
  • [22] Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation
    Daniele Bergamaschi
    Yardena Samuels
    Shan Zhong
    Xin Lu
    Oncogene, 2005, 24 : 3836 - 3841
  • [23] Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis
    Khan, M. N.
    Bhattacharyya, T.
    Andrikopoulos, P.
    Esteban, M. A.
    Barod, R.
    Connor, T.
    Ashcroft, M.
    Maxwell, P. H.
    Kiriakidis, S.
    BRITISH JOURNAL OF CANCER, 2011, 104 (07) : 1151 - 1159
  • [24] Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis
    M N Khan
    T Bhattacharyya
    P Andrikopoulos
    M A Esteban
    R Barod
    T Connor
    M Ashcroft
    P H Maxwell
    S Kiriakidis
    British Journal of Cancer, 2011, 104 : 1151 - 1159
  • [25] Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation
    Bergamaschi, D
    Samuels, Y
    Zhong, S
    Lu, X
    ONCOGENE, 2005, 24 (23) : 3836 - 3841
  • [26] Detection and characterization of a dominant-negative oncogenic splice variant of the Apoptosis-Stimulating Protein of p53-2 (ASPP2) in colorectal cancer (CRC)
    Rieger, I
    Tsintari, V
    Schittenhelm, M. M.
    Kampa-Schittenhelm, K. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 286 - 287
  • [27] ASPP1 and ASPP2: Common activators of p53 family members
    Bergamaschi, D
    Samuels, Y
    Jin, BQ
    Duraisingham, S
    Crook, T
    Lu, X
    MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (03) : 1341 - 1350
  • [28] Control of ASPP2/53BP2L protein levels by proteasomal degradation modulates p53 apoptotic function
    Zhu, ZY
    Ramos, J
    Kampa, K
    Adimoolam, S
    Sirisawad, M
    Yu, ZY
    Chen, DX
    Naumovski, L
    Lopez, CD
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (41) : 34473 - 34480
  • [29] Identification and characterization of an apoptosis-stimulating protein of p53 (ASPP) gene from Branchiostoma belcheri: Insights into evolution of ASPP gene family
    Song, Xiaojun
    Du, Juan
    Zhu, Wei
    Jin, Ping
    Ma, Fei
    FISH & SHELLFISH IMMUNOLOGY, 2016, 49 : 268 - 274
  • [30] Apoptosis Stimulating Protein of p53 (ASPP2) Heterozygous Mice Are Lymphoma-Prone and Display Attenuated Apoptosis and Cell Cycle Checkpoints.
    Kampa, Kerstin Maria
    Acoba, Jared
    Chen, Dexi
    Lee, Hun-Joo
    Beemer, Kelly
    Gay, Joel
    Zhu, Zhyi
    Padiernos, Emerson
    Schittenhelm, Marcus M.
    Kanz, Lothar
    Corless, Christopher
    Lopez, Charles
    BLOOD, 2008, 112 (11) : 982 - 982